Archive

Archive for the ‘drug safety’ Category

Lilly’s CEO Calls for Reform of Nation’s Drug Safety System

October 2nd, 2007

FDA, health care industry, and the medical community collaboration would share data via a national health IT system

CLEVELAND, October 02, 2007 /PRNewswire-FirstCall/ — Sidney Taurel, chairman and chief executive officer, Eli Lilly and Company, in a speech today at the Cleveland Clinic, called on the health care industry, medical community and U.S. government to actively collaborate on a health information technology system that would provide more rapid and useful insights on the effectiveness of medicines while improving drug safety.

His proposal, along with other benefits that would flow from a true healthcare “Information Revolution,” was outlined for an audience of some of the nation’s medical thought-leaders attending Cleveland Clinic’s 2007 Medical Innovations Summit. Taurel was the keynote speaker.

“The use of prescription medicines always will be a matter of balancing benefits and risks,” Taurel said. “Fortunately, systems are now within our grasp to more quickly identify both the true benefits and the full extent of risks associated with medicines in widespread use.”

Read more about Taurel’s drug safety proposal.

drug safety

Relsys and Sentrix Extend Drug Safety Partnership

June 18th, 2007

Pharma Marketletter
June 18, 2007

USA-based firms Relsys International and Sentrix are to extend their pharmacovigilance and risk management accord to include Relsys’ Argus Safety web-based compliance technology. The model is designed to …

Read more about this drug safety partnership.

drug safety

Pharmaceutical Companies Expanding Post-Market Drug Safety Initiatives to Prevent Adverse Reactions, Finds PricewaterhouseCoopers Study

January 7th, 2007

January 30, 2007

Pharmacovigilance Seen as Complementing Pre-Approval Testing

Heightened public awareness of drug safety, greater regulatory scrutiny and a number of recent drug withdrawals and black box warnings are causing pharmaceutical companies to rethink how they ensure the post-market safety of their products. Instead of relying solely on pre-approval clinical trials and the federal drug approval process, pharmaceutical companies are shifting to “pharmacovigilance” - continued, systematic monitoring of drug safety under real-world conditions, according to “Unlocking the Power of Pharmacovigilance,” a new PricewaterhouseCoopers report.

Read the rest of this article on drug safety initiatives.

drug safety